Compare Cytokinetics Inc (CYTK) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Five Below Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.50B), while Five Below Inc trades at $209.72 (market cap $11.25B). The key difference: Five Below Inc is the larger of the two by market cap, and Five Below Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Five Below Inc for 46 Days on average.
| CYTK | FIVE | |
|---|---|---|
Market Cap | $8.50B | $11.25B |
Volume | 2,395,556 | 986,546 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $262.72 |
52-Week Low | $54.76 | $138.49 |
Typical Hold Time | 19 Days | 46 Days |
Enterprise Value | $8.60B | $12.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Five Below (FIVE) trades at $204.24, down 2.71% today but maintains strong analyst support with 60% buy ratings and a $298.44 consensus price target. The company shows robust revenue growth from $3.88B in 2025 to projected $5.3B in 2026, with earnings beating expectations in three consecutive quarters. Technical indicators show bearish momentum despite oversold RSI readings, with key support at $197.
FIVE presents a compelling growth story with expanding margins and strategic initiatives, though premium valuation (P/E 18.32) and execution risks warrant caution. The stock offers significant upside to analyst targets but faces near-term technical pressure and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
